Bromoacetamido-PEG4-Acid manufacturers
- BrCH2CONH-PEG4-acid
-
-
2025-06-07
- CAS:1807518-67-7
- Min. Order: 1g
- Purity: >98.00%
- Supply Ability: 1g
|
| | Bromoacetamido-PEG4-Acid Basic information |
| Product Name: | Bromoacetamido-PEG4-Acid | | Synonyms: | Bromoacetamido-PEG4-Acid;Bromoacetamido-PEG5-acid;Bromoacetamido-PEG4-CH2CH2COOH;CAS_1807518-67-7;BrCH2CONH-PEG4-acid;1-Bromo-2-oxo-6,9,12,15-tetraoxa-3-azaoctadecan-18-oic acid;Bromoacetamido-PEG4-CH2CH2COOH/Propanoic acid, 3-[(14-bromo-13-oxo-3,6,9-trioxa-12-azatetradec-1-yl)oxy]-;Propanoic acid, 3-[(14-bromo-13-oxo-3,6,9-trioxa-12-azatetradec-1-yl)oxy]- | | CAS: | 1807518-67-7 | | MF: | C13H24BrNO7 | | MW: | 386.24 | | EINECS: | | | Product Categories: | | | Mol File: | 1807518-67-7.mol |  |
| | Bromoacetamido-PEG4-Acid Chemical Properties |
| Boiling point | 557.7±50.0 °C(Predicted) | | density | 1.368±0.06 g/cm3(Predicted) | | storage temp. | Storage temp. 2-8°C | | solubility | Soluble in Water, DCM | | form | Viscous Liquid | | pka | 4.28±0.10(Predicted) | | color | Colorless to light yellow |
| | Bromoacetamido-PEG4-Acid Usage And Synthesis |
| Description | Bromoacetamido-PEG4-acid is a PEG linker containing a bromide group and a terminal carboxylic acid. The hydrophilic PEG spacer increases solubility in aqueous media. The bromide (Br) is a very good leaving group for nucleophilic substitution reactions. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond. | | Uses | Bromoacetamido-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. Bromoacetamido-PEG4-acid is also a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[2]. | | IC 50 | PEGs; Cleavable Linker | | References | [1] An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562. DOI:10.1016/j.ebiom.2018.09.005
[2] Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. DOI:10.1038/nrd.2016.268 |
| | Bromoacetamido-PEG4-Acid Preparation Products And Raw materials |
|